During the last session, Passage Bio Inc. (NASDAQ:PASG)’s traded shares were 0.3 million. At the end of the trading day, the stock’s price was $2.22, reflecting an intraday gain of 4.23% or $0.09. The 52-week high for the PASG share is $13.07, that puts it down -488.74 from that peak though still a striking 29.28% gain since the share price plummeted to a 52-week low of $1.57. The company’s market capitalization is $137.35M, and the average intraday trading volume over the past 10 days was 0.21 million shares, and the average trade volume was 466.83K shares over the past three months.
Passage Bio Inc. (PASG) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. PASG has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
Passage Bio Inc. (NASDAQ:PASG) trade information
Passage Bio Inc. (PASG) registered a 4.23% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.23% in intraday trading to $2.22 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 18.72%, and it has moved by -10.12% in 30 days. Based on these gigs, the overall price performance for the year is -82.44%. The short interest in Passage Bio Inc. (NASDAQ:PASG) is 1.32 million shares and it means that shorts have 2.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $9.57, which implies an increase of 76.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $18.00 respectively. As a result, PASG is trading at a discount of -710.81% off the target high and 9.91% off the low.
Passage Bio Inc. (PASG) estimates and forecasts
Statistics show that Passage Bio Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Passage Bio Inc. (PASG) shares have gone down -51.63% during the last six months, with a year-to-date growth rate more than the industry average at 6.03% against 1.00.
While earnings are projected to return -19.60% in 2022.
Passage Bio Inc. is due to release its next quarterly earnings between November 02 and November 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Passage Bio Inc. (NASDAQ:PASG)’s Major holders
Passage Bio Inc. insiders own 9.75% of total outstanding shares while institutional holders control 80.64%, with the float percentage being 89.35%. Orbimed Advisors LLC. is the largest shareholder of the company, while 159 institutions own stock in it. As of Mar 30, 2022, the company held over 7.33 million shares (or 13.50% of all shares), a total value of $16.28 million in shares.
The next largest institutional holding, with 5.01 million shares, is of Frazier Life Sciences Management, L.P. ‘s that is approximately 9.22% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $11.12 million.
Also, the Mutual Funds coming in first place with the largest holdings of Passage Bio Inc. (PASG) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 1.03 million shares. This amounts to just over 1.89 percent of the company’s overall shares, with a $2.28 million market value. The same data shows that the other fund manager holds slightly less at 0.82 million, or about 1.52% of the stock, which is worth about $1.83 million.